(Q33348261)

26 July 2017

title

Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer (English)

1 reference

26 July 2017

1 reference

1 reference

8

Hisashi Noguchi

1 reference

26 July 2017

Takashi Hirose

1

1 reference

26 July 2017

Naoya Horichi

2

1 reference

26 July 2017

Tohru Ohmori

3

1 reference

26 July 2017

Keiichi Ogura

4

1 reference

26 July 2017

Takamichi Hosaka

5

1 reference

26 July 2017

Kohichi Ando

6

1 reference

26 July 2017

Hiroo Ishida

7

1 reference

26 July 2017

Mitsuru Adachi

9

1 reference

26 July 2017

publication date

1 June 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

40

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

333-338

1 reference

Management of small-cell cancer of the lung

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Second-line chemotherapy and its evaluation in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900075-8

7 January 2021

10.1016/S0169-5002(03)00075-8

Identifiers

DOI

1 reference

26 July 2017

1 reference